Napatkamon Ayutyanont

发表

Opioid Utility and Hospital Outcomes Among Inpatients Admitted With Osteoarthritis and Spine Disorders

Mingon Kang, N. Ayutyanont, Se won Lee, 2022, American journal of physical medicine & rehabilitation.

Ushering in the study and treatment of preclinical Alzheimer disease

Richard J. Caselli, Kewei Chen, Napatkamon Ayutyanont, 2013, Nature Reviews Neurology.

Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

G. Alexander, S. DeKosky, W. Klunk, 2009, Proceedings of the National Academy of Sciences.

Characterizing Alzheimer's disease using a hypometabolic convergence index

Paul M. Thompson, et al., Clifford R. Jack, 2011, NeuroImage.

The Effect of Adding Procalcitonin to the Systemic Inflammatory Response Syndrome (Sirs) and Quick Sepsis-Related Organ Failure Assessment (qSOFA) Scoring System in Predicting Sepsis Mortality

Pinaky N Shah, N. Ayutyanont, Andrew Kim, 2022, Cureus.

Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona

R. Gish, N. Ayutyanont, L. Jayaram, 2017, BMJ open gastroenterology.

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Kewei Chen, Eric M Reiman, Napatkamon Ayutyanont, 2011, Archives of neurology.

Abuse and neglect of people with multiple sclerosis: A survey with the North American Research Committee on Multiple Sclerosis (NARCOMS).

D. Sorkin, N. Ayutyanont, L. Mosqueda, 2020, Multiple sclerosis and related disorders.

An Assessment of the Diagnostic Value in Syncope Workup: A Retrospective Study

H. Akhondi, A. Hatharasinghe, K. Etebar, 2021, HCA Healthcare Journal of Medicine.

Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Kewei Chen, Eric M Reiman, Richard J Caselli, 2011, Journal of Alzheimer's disease : JAD.

An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease

Kewei Chen, Napatkamon Ayutyanont, Adam S. Fleisher, 2014, Alzheimer's & Dementia.

The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

A. Fleisher, P. Tariot, E. Reiman, 2014, The Journal of clinical psychiatry.

Brain glucose and acetoacetate metabolism: a comparison of young and older adults

Napatkamon Ayutyanont, Eric Turcotte, Christian-Alexandre Castellano, 2014, Neurobiology of Aging.

Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative

Michael W. Weiner, Paul M. Thompson, Danielle J. Harvey, 2010, NeuroImage.

Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ε4 gene dose in cognitively normal adults: A cross-validation study using voxel-based multi-modal partial least squares

Richard J. Caselli, Adam Fleisher, Gene E. Alexander, 2012, NeuroImage.

Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease

Keith A. Johnson, R. Coleman, M. Mintun, 2013, Neurobiology of Aging.

Association between an Alzheimer’s Disease-Related Index and APOE ε4 Gene Dose

Richard J. Caselli, Gene E. Alexander, Kewei Chen, 2013, PloS one.

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

Rebecca A. Reiman, A. Fleisher, P. Tariot, 2012, The Lancet Neurology.

Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

A. Fagan, A. Fleisher, P. Tariot, 2015, JAMA neurology.

Validity and Reliability of the Scale to Report Emotional Stress Signs-Multiple Sclerosis (STRESS-MS) in Assessing Abuse and Neglect of Adults With Multiple Sclerosis.

D. Sorkin, N. Ayutyanont, L. Mosqueda, 2021, International journal of MS care.

Impact of the COVID-19 Pandemic on Trauma Encounters

N. Ayutyanont, D. Plurad, A. Mahmoud, 2021, The American surgeon.

Effect of Resident Involvement on Trauma Patient Outcomes: A Single-Institution Review.

N. Ayutyanont, D. Plurad, Tommy Y. Kim, 2022, Journal of surgical education.

Clinical and multimodal biomarker correlates of ADNI neuropathological findings

Christos Davatzikos, Eric M Reiman, Kewei Chen, 2013, Acta Neuropathologica Communications.

The Transverse Infrapatellar View: A New Ultrasound Technique to Measure Distal Femoral Cartilage Thickness

N. Ayutyanont, Se won Lee, S. Kim, 2020, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Linking functional and structural brain images with multivariate network analyses: A novel application of the partial least square method

Richard J. Caselli, Gene E. Alexander, Daniel Bandy, 2009, NeuroImage.

Clinical characteristics, hospital course, and disposition of patients with nontraumatic spinal cord injury in a large private health care system in the United States

N. Ayutyanont, Se won Lee, J. Holt, 2022, The journal of spinal cord medicine.

Critical care ultrasound: A national survey across specialties

N. Ayutyanont, J. Stowell, J. Kendall, 2018, Journal of clinical ultrasound : JCU.

Establishing Composite Cognitive Endpoints for Use in Preclinical Alzheimer's Disease Trials.

P. Tariot, D. Bennett, E. Reiman, 2015, The journal of prevention of Alzheimer's disease.

Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI

Cindee M. Madison, W. Jagust, G. Frisoni, 2014, Alzheimer disease and associated disorders.

Characterizing Alzheimer's disease using a hypometabolic convergence index

C. Jack, G. Alexander, D. Harvey, 2011, NeuroImage.

Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region

Daniel Bandy, Eric M Reiman, Robert A Koeppe, 2015, The Journal of Nuclear Medicine.